(20-Diphenylphosphanyl-8,15-dioxatricyclo[14.4.0.02,7]icosa-1(16),2,4,17,19-pentaen-3-yl)-diphenylphosphane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (20-Diphenylphosphanyl-8,15-dioxatricyclo[14.4.0.02,7]icosa-1(16),2,4,17,19-pentaen-3-yl)-diphenylphosphane
• 英文别名: (20-diphenylphosphanyl-8,15-dioxatricyclo[14.4.0.02,7]icosa-1(16),2,4,17,19-pentaen-3-yl)-diphenylphosphane
• 化学式: C₄₂H₄₀O₂P₂
• 分子量: 638.7
• InChiKey: YXUXZEOTKUIXOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  46
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Processes for Preparing Jak Inhibitors and Related Intermediate Compounds
  申请人：Incyte Holdings Corporation

  公开号：US20210253584A1

  公开（公告）日：2021-08-19

  The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.